Efficacy and Safety of Envafolimab Combined With Doxorubicin and Ifosfamide as First-line Treatment for Advanced Soft Tissue Sarcoma
Efficacy and Safety of Envafolimab Combined With Doxorubicin and Ifosfamide as First-line Treatment for Advanced Soft Tissue Sarcoma is a PHASE2 clinical asset sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University in Soft Tissue Sarcoma. SEO and diligence focus: Envafolimab combined with an AI regimen (doxorubicin and ifosfamide), endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Indication: Soft Tissue Sarcoma
Modality: small molecule
Target: Envafolimab combined with an AI regimen (doxorubicin and ifosfamide)
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 28, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Envafolimab combined with an AI regimen (doxorubicin and ifosfamide)
View original source fields
Condition raw: Soft Tissue Sarcoma
Condition normalized: Soft Tissue Sarcoma
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Envafolimab combined with an AI regimen (doxorubicin and ifosfamide)
Target normalized: Envafolimab combined with an AI regimen (doxorubicin and ifosfamide)